ACAD
35.83
-0.9
-2.45%
AEMD
0.98
0.00
0.00%
APRI
1.82
-0.08
-4.21%
ARNA
27.31
-0.25
-0.91%
ATEC
4.12
-0.01
-0.24%
CNAT
5.01
-0.14
-2.72%
CRXM
0.103
-0.034
-24.8758%
CYTX
0.465
-0.021
-4.321%
DXCM
44.98
+0.03
+0.07%
GNMK
7.84
-0.22
-2.73%
HALO
17.77
+0.05
+0.28%
ILMN
205.18
-0.44
-0.21%
INNV
0.087
-0.003
-3.010%
INO
6.25
-0.07
-1.11%
ISCO
1.54
+0.03
+1.99%
ISIS
57.56
0.00
0.00%
LGND
143.35
-0.81
-0.56%
LPTN
2.93
-2.93
-100.00%
MBVX
0.74
+0.025
+3.4685%
MEIP
2.62
+0.14
+5.65%
MNOV
6.19
-0.19
-2.98%
MRTX
15.55
+1.2
+8.36%
MSTX
0.13
-0.01
0.00%
NBIX
58.96
-0.46
-0.77%
NUVA
54.57
+0.39
+0.72%
ONCS
1.29
+0.01
+0.78%
ONVO
1.4
-0.08
-5.41%
OREX
1.82
-0.05
-2.67%
OTIC
3.475
+0.025
+0.725%
QDEL
41.95
+0.24
+0.58%
RCPT
231.96
0.00
0.00%
RGLS
1.25
-0.07
-5.30%
RMD
78.79
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.24
0.00
-0.13%
SRNE
2.5
-0.1
-3.85%
TROV
0.809
-0.059
-6.7742%
VICL
2.38
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
39.65
+0.65
+1.67%
ACAD
35.83
-0.9
-2.45%
AEMD
0.98
0.00
0.00%
APRI
1.82
-0.08
-4.21%
ARNA
27.31
-0.25
-0.91%
ATEC
4.12
-0.01
-0.24%
CNAT
5.01
-0.14
-2.72%
CRXM
0.103
-0.034
-24.8758%
CYTX
0.465
-0.021
-4.321%
DXCM
44.98
+0.03
+0.07%
GNMK
7.84
-0.22
-2.73%
HALO
17.77
+0.05
+0.28%
ILMN
205.18
-0.44
-0.21%
INNV
0.087
-0.003
-3.010%
INO
6.25
-0.07
-1.11%
ISCO
1.54
+0.03
+1.99%
ISIS
57.56
0.00
0.00%
LGND
143.35
-0.81
-0.56%
LPTN
2.93
-2.93
-100.00%
MBVX
0.74
+0.025
+3.4685%
MEIP
2.62
+0.14
+5.65%
MNOV
6.19
-0.19
-2.98%
MRTX
15.55
+1.2
+8.36%
MSTX
0.13
-0.01
0.00%
NBIX
58.96
-0.46
-0.77%
NUVA
54.57
+0.39
+0.72%
ONCS
1.29
+0.01
+0.78%
ONVO
1.4
-0.08
-5.41%
OREX
1.82
-0.05
-2.67%
OTIC
3.475
+0.025
+0.725%
QDEL
41.95
+0.24
+0.58%
RCPT
231.96
0.00
0.00%
RGLS
1.25
-0.07
-5.30%
RMD
78.79
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.24
0.00
-0.13%
SRNE
2.5
-0.1
-3.85%
TROV
0.809
-0.059
-6.7742%
VICL
2.38
0.00
0.00%
VOLC
18
0.00
0.00%
ZGNX
39.65
+0.65
+1.67%
Home » Archive by Category

Syndication

Global Field Applications Scientist (FAS) Manager (Open)

October 12, 2017 – 8:31 am

Reporting to the Vice President of Marketing, the ideal candidate should have experience working in a life science instruments company that develops, supports, or sells liquid handling instruments or similar. The individual must be able to communicat …

UC San Diego Celebrates Oldest Living Alumnus Walter Munk as He Turns 100

October 12, 2017 – 6:00 am

If you’ve ever checked a surf report to know how big the waves will be for a surfing session, you have Walter Munk to thank. And those calendars that predict high and low tides? They wouldn’t be possible without the research from a UC San Diego legendary oceanographer.

Spruce Biosciences Provides Corporate Update on Series A Venture Financing, Leadership Team and Lead Clinical Program

October 12, 2017 – 4:00 am

Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia

SAN FRANCISCO, Oct. 12, 2017 /PRNewswire/ — Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today provided a corporate update, building upon a previously closed Series A financing of $20 million to expand its leadership team and advance its lead product candidate, SPR001, into advanced clinical trials.

The Spruce team, co-founded by Chief Executive Officer Alexis Howerton, Ph.D., is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases. The Company’s lead indication, congenital adrenal hyperplasia (CAH), is caused by genetic mutations that result in the inability to produce the critical ‘stress’ hormone cortisol. Although CAH is part of the newborn screening program, there are currently no FDA-approved therapies for CAH. CAH is typically treated with chronic, high-dose steroids which often result in significant side effects and long-term health consequences.

Spruce closed a $20 million Series A financing in 2016, led by Novo Holdings A/S with additional investment from RiverVest Venture Partners. That financial runway has since enabled the company to complete the licensing of SPR001, together with a substantial body of nonclinical and clinical data, and initiate a Phase 2 clinical trial to study the safety and efficacy of SPR001 in adults with classic CAH. This study is currently enrolling at centers across the United States, with initial data expected in 2018.

Concurrent with the financing, Tiba Aynechi, Ph.D. from Novo Ventures (US) Inc. and Niall O’Donnell, Ph.D. from RiverVest joined the Board of Directors. Earlier this year, Mike Grey was named Executive Chairman. Mr. Grey has founded and held leadership positions in a number of biopharmaceutical companies, including Lumena Pharmaceuticals, Inc., and brings more than 40 years of experience in the pharmaceutical and biotechnology industries.

“Our investors were attracted to our novel small molecule drug candidate because it has a clinically-verified mechanism of action with the potential to improve hormone levels, reduce steroid use and greatly enhance quality of life for patients that have been traditionally underserved. We are pleased that in under 18 months we’ve been successful in using the initial financing to build out our clinical and operational expertise and advance SPR001 into Phase 2,” said CEO Dr. Howerton.

Spruce also recently expanded its leadership team to appoint Michael Huang, MD, as its Chief Medical Officer. Dr. Huang has more than 10 years of clinical research experience in all phases of drug development and has provided leadership resulting in several successful drug approvals prior to joining Spruce. Most recently, Dr. Huang served as Vice President of Clinical Development at Regulus Therapeutics. Prior to Regulus, Dr. Huang held positions of increasing responsibility at Spectrum Pharmaceuticals, Santarus and Auspex Pharmaceuticals.

“I am thrilled to join Spruce and help advance a promising new therapeutic with the potential to treat a serious disease left virtually untouched by the biotech industry. I look forward to working with Spruce’s talented and motivated team to unlock our capacity for developing new medicines for patients suffering from rare endocrine diseases with limited treatment alternatives,” stated Dr. Huang.

For more information on Spruce Biosciences, please visit sprucebiosciences.com.

About Spruce Biosciences
Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. The Spruce team is leveraging their extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from rare endocrine diseases. Spruce’s lead product candidate, SPR001, has a novel and clinically verified mechanism of action (MOA) and is currently in Phase 2 clinical trials for congenital adrenal hyperplasia, a rare disease that is screened in newborns and for which there is not yet an FDA-approved therapy. The Company is headquartered in San Francisco and closed a Series A Financing of $20 million in 2016. For more information on Spruce, please visit sprucebiosciences.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/spruce-biosciences-provides-corporate-update-on-series-a-venture-financing-leadership-team-and-lead-clinical-program-300535279.html

SOURCE Spruce Biosciences

OncoSec to Present Updated Clinical and Immune Biomarker Data from its Monotherapy and Combination Therapy Studies with ImmunoPulse┬« IL-12 at the 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research

October 12, 2017 – 4:00 am

OncoSec presented at the 2nd Annual Biomarkers & Precision Medicine USA Congress

SAN DIEGO, Oct. 12, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present new clinical data on ImmunoPulse® IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or “tavo”] with electroporation), its lead program focused on oncology, at the upcoming 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research (SMR). In addition, Chris Twitty, Ph.D., Executive Director of Clinical Science, gave an oral presentation at the 2nd Annual Biomarkers & Precision Medicine USA Congress earlier this week.

“We are excited to share updated data from our phase 2 clinical monotherapy trial with ImmunoPulse IL-12 in patients with stage III/IV melanoma,” said Punit Dhillon, CEO and President at OncoSec. “These data, along with the emerging clinical data from the phase 2 combination study, further support the rationale for our global, open-label, registration directed phase 2b clinical trial, PISCES/KEYNOTE-695, which we anticipate reporting initial data in mid-2018.”

9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research

Dr. Alain Algazi, Associate Professor, Department of Medicine (Hematology/Oncology), at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, will give an oral presentation contrasting monotherapy ImmunoPulse IL-12 to its combination with pembrolizumab. The presentation includes an assessment of clinical and immune biomarker data from the company’s recently completed monotherapy phase 2 trial. The 9th World Congress of Melanoma – A Joint Meeting with the Society for Melanoma Research (SMR) is to be held on October 18-22, 2017, in Brisbane, Australia.

Details of the presentation are as follows:

Abstract Title: Clinical Immune Monitoring and Biomarker Data of pIL-12 Monotherapy Compared to pIL-12 with Pembrolizumab in Metastatic Melanoma Supports the Rationale for Combination Therapy (Abstract # FC05-3)

Session Title: Biology and Biomarkers  

Date and Time: October 19, 2017 at 3:30 PM3:40 PM

Location: Brisbane Convention & Exhibition Centre

Dr. Algazi will present new clinical and immune monitoring data from patients treated with ImmunoPulse IL-12, as a monotherapy (n=51 patients) versus the combination of ImmunoPulse IL-12 and the approved anti-PD-1 therapy pembrolizumab (n=22 patients) to better understand the mechanisms associated with each immunotherapy protocol.  In the 51 patients treated with ImmunoPulse IL-12 as monotherapy, an average of 33.5% best overall response rate (BORR) at 180 days by a modified “skin” RECIST was demonstrated, in addition to a favorable safety profile (no life threatening or grade 4 AE). In the combination trial of 22 patients treated to date, a 48% BORR was observed at 24 weeks. Biomarker analyses suggest ImmunoPulse IL-12 drives a cellular response leading to an inflamed tumor with an increased TIL frequency whether as a monotherapy or combined with pembrolizumab, converting “cold” tumors to “hot”.

Further details on this presentation will be provided in upcoming Company communications. For more information about this conference, please visit: https://worldmelanoma2017.com

2nd Annual Biomarkers & Precision Medicine USA Congress

Chris Twitty, Ph.D., Executive Director of Clinical Science at OncoSec, gave an oral presentation entitled: “Interrogation of the tumor microenvironment and associated immunity in patients with melanoma” in addition to leading a panel discussion at the 2nd Annual Biomarkers & Precision Medicine USA Congress on October 10, 2017 at the Hilton San Diego Mission Valley Hotel in San Diego, CA. For more information, please visit: https://www.biomarkersusa-congress.com/.

About OncoSec Medical Incorporated:

OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or “tavo”). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program’s current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.

CONTACT:

Investor Relations 
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

Media Relations 
OncoSec Medical Incorporated
855-662-6732

 

View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-updated-clinical-and-immune-biomarker-data-from-its-monotherapy-and-combination-therapy-studies-with-immunopulse-il-12-at-the-9th-world-congress-of-melanoma–a-joint-meeting-with-the-society-for-melanoma-resea-300535541.html

SOURCE OncoSec Medical Incorporated

Clinical Biostatistician – Polaris Pharmaceuticals – San Diego, CA

October 12, 2017 – 12:58 am

Is a multinational biotechnology company specializing in the research and development of novel pharmaceuticals to treat cancer. Polaris Pharmaceuticals, Inc….From Polaris Pharmaceuticals – Thu, 12 Oct 2017 08:58:57 GMT – View all San Diego, CA jobs

GMP Assistant Chemist – TriLink Biotechnologies – San Diego, CA

October 12, 2017 – 12:12 am

We our seeking an individual to join our oligonucleotide production team. A Bachelor’s of Science in a scientific field is required, Chemistry or Biology is…
From TriLink Biotechnologies – Thu, 12 Oct 2017 08:12:05 GMT – View all San Diego, CA jobs

Title Clinical Data Manager – ProSciento, Inc. – San Diego, CA

October 11, 2017 – 7:14 pm

Bachelor’s degree in life sciences or mathematics and/or formal or on-the-job training in clinical trial methodology and Good Clinical Practice (GCP) plus five…
From ProSciento, Inc. – Thu, 12 Oct 2017 03:14:12 GMT – View all San Diego, CA jobs

Protagonist Therapeutics Prices Public Offering of Common Stock

October 11, 2017 – 6:26 pm

NEWARK, Calif., Oct. 11, 2017 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biopharmaceutical company that discovers and develops novel peptide-based drugs, announced today that it has priced an underwritten public offering of 3,530,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Protagonist from the offering, before underwriting discounts and commissions and offering costs, are expected to be $60,010,000. Protagonist has granted the underwriters a 30-day option to purchase up to an additional 529,500 shares of common stock. All of the shares to be sold in the offering are being sold by Protagonist. The offering is expected to close on or about October 16, 2017, subject to satisfaction of customary closing conditions. Protagonist intends to use the net proceeds from the proposed offering to fund clinical research and development of the company’s three therapeutic candidates, PTG-100, PTG-200, and PTG-300, including the completion of ongoing clinical trials, discovery programs and platform development, and for working capital and general corporate purposes.

Leerink Partners LLC and Barclays Capital Inc. are acting as joint lead book-running managers for the offering.  BMO Capital Markets Corp. and Stifel are acting as passive joint book-running managers for the offering. BTIG LLC and Nomura Securities International, Inc. are acting as co-lead managers for the offering.

The securities described above are being offering by Protagonist pursuant to a shelf registration statement, including a base prospectus, filed by Protagonist with the Securities and Exchange Commission (SEC) and declared effective by the SEC on October 5, 2017. A preliminary prospectus supplement and the accompanying prospectus relating to this offering has been filed with the SEC and a final prospectus supplement and accompanying prospected related to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by telephone at (800) 808-7525, ext. 6132; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, email: Barclaysprospectus@broadridge.com; from BMO Capital Markets Corp., by telephone at 800-414-3627 or by email at bmoprospectus@bmo.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.  

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there by any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Protagonist Therapeutics

Protagonist is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Protagonist’s lead peptide candidates, PTG-100 and PTG-200, are based on this approach. PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company plans to initiate clinical trials of PTG-200 in 2017 as a potential treatment for Crohn’s disease.  The company recently entered into a worldwide collaboration with Janssen Biotech, Inc. to co-develop and commercialize PTG-200.  Protagonist is also developing an injectable hepcidin mimetic, PTG-300, for the treatment of rare diseases such as beta-thalassemia and myelodysplastic syndromes, currently in a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the completion of the proposed public offering. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “expect,” or the negative or plural of these words or similar expressions.  Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, the satisfaction of customary closing conditions and the anticipated use of proceeds.  We discuss many of these risks in greater detail under the heading “Risk Factors” contained in the preliminary prospectus supplement, and accompanying prospectus, related to the offering filed with the SEC on October 11, 2017, and other filings with the SEC. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-prices-public-offering-of-common-stock-300535373.html

SOURCE Protagonist Therapeutics, Inc.

Material Handler Associate

October 11, 2017 – 3:40 pm

Invivoscribe Technologies, Inc., is a privately-held corporation dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular research, molecular diagnostics, and personalized molecu …

Sales Manager – Pipette.com – San Diego, CA

October 11, 2017 – 2:41 pm

Pipette.com has been consistently growing 15-20% every year for the past 5 years and is looking to expand its distribution division for the Oxford, CAPP and…From Indeed – Wed, 11 Oct 2017 22:41:04 GMT – View all San Diego, CA jobs